文献速递造血干细胞移植与细胞治疗

慢性GVHD联盟CATCH研究:发病率、初始表现及危险因素

Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development.
PubMed 文献 · Blood Adv · 2026-01-01

这项前瞻性多中心观察研究纳入208例异基因造血干细胞移植患者,24个月时任何慢性GVHD累积发病率为54%,需系统免疫抑制治疗者为38%。起病时最常累及口腔(42%)、眼(41%)和皮肤(32%),总体严重程度以轻度(55%)为主。后续需系统免疫抑制治疗与供受者CMV阳性、非移植后环磷酰胺为基础的急性GVHD预防及系列器官评分和LSS变化相关。

要点

  • 移植后24个月任何慢性GVHD累积发病率为54%,需系统免疫抑制治疗者为38%。
  • 起病时口腔、眼、皮肤最常受累,总体严重程度以轻度为主。
  • 供受者CMV阳性及非PT-Cy为基础的急性GVHD预防与后续需系统免疫抑制治疗相关。

核心结论

  • 当前时代异基因造血干细胞移植后慢性GVHD累积发病率仍较高,24个月时任何慢性GVHD为54%,需系统免疫抑制治疗者为38%。

研究设计与样本

  • 前瞻性、多中心、观察性研究,共纳入7个移植中心的208例受试者,移植前入组,移植后第一年约每2个月评估一次,并在慢性GVHD诊断时评估。

主要发现

  • 24个月时任何慢性GVHD累积发病率为54%,需系统免疫抑制治疗的慢性GVHD为38%。
  • 起病时器官受累比例:口腔42%、眼41%、皮肤32%、肝17%、肺11%、胃肠道9%、关节/筋膜5%。
  • 起病时总体严重程度:轻度(或以下)55%、中度37%、重度8%。
  • 后续需系统免疫抑制治疗的慢性GVHD与基线供受者CMV阳性及非移植后环磷酰胺为基础的急性GVHD预防显著相关。
  • 后续需系统免疫抑制治疗的慢性GVHD还与皮肤/口腔/关节( photographic range of motion)器官评分及LSS总结评分的系列变化相关。

临床怎么用

  • 应关注移植后口腔、眼和皮肤等慢性GVHD常见起病器官的早期表现。
  • 对供受者CMV阳性或采用非移植后环磷酰胺为基础急性GVHD预防的患者,需警惕后续需系统免疫抑制治疗的慢性GVHD。
  • 系列监测皮肤/口腔/关节器官评分及LSS评分变化可能有助于识别后续需系统免疫抑制治疗的风险。

局限性

  • 原文未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of chronic graft-versus-host disease (GVHD) is declining, but up to 30% of GVHD survivors are still diagnosed with chronic GVHD. We conducted a prospective, multicenter, and observational study to understand the incidence and earliest presenting signs and symptoms of chronic GVHD in the current era to inform trials testing early therapies. Patients were enrolled and assessed before allogeneic hematopoietic cell transplantation (HCT), approximately every 2 months through the first year after HCT, and at the time of chronic GVHD diagnosis. Clinician assessments, patient-reported measures (Lee Symptom Scale [LSS], Patient-Reported Outcomes Measurement Information System), and biologic samples were collected at each time point. A total of 208 subjects were enrolled across 7 HCT centers. The cumulative incidence of any chronic GVHD was 54% by 24 months after HCT, whereas chronic GVHD requiring systemic immunosuppressive therapy (IST) was 38%. At onset, organ involvement included skin (32%), eyes (41%), mouth (42%), liver (17%), gastrointestinal tract (9%), lungs (11%), and joint/fascia (5%), with an overall severity of mild (or less) in 55%, moderate in 37%, or severe in 8% of patients. Management practices were heterogeneous. Subsequent chronic GVHD requiring IST was significantly associated with baseline donor/recipient cytomegalovirus positivity and nonposttransplant cyclophosphamide-based acute GVHD prophylaxis, as well as serial changes in skin/mouth/joint (photographic range of motion) organ scores and the LSS summary score. These data provide current estimates of chronic GVHD incidence and presenting features, new data on risk predictors, and a data resource for future overall and organ-specific biomarker studies. This trial was registered at www.clinicaltrials.gov as NCT04188912.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pidala J, Hamilton BK, Chen GL, et al. Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development. Blood Adv. 2026. PMID: 42486676. doi:10.1182/bloodadvances.2026021346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。